Infinity Clinical Research

The PROGRESS study is being done to find out the efficacy of an investigational drug called LX9211 in reducing pain related to diabetic peripheral neuropathy.

LX9211 is a new type of investigational drug called an AP2-associated protein kinase 1 inhibitor (AAK1 inhibitor). It is believed that inhibiting AAK1 may help reduce pain caused by diabetic neuropathy.

You may qualify to participate if you:
• Are 18 years of age or older
• Have type 1 or type 2 diabetes
• Have an A1C less than or equal to 11%
• Have ongoing diabetic peripheral neuropathy with moderate to severe pain

Your medical history and other criteria will be checked to see if you can take part in the study.

The study lasts about 16 weeks. Qualified participants will not have to pay for the study drug, study visits, or for the procedures or tests that are needed as part of this study. Additionally, you may be compensated for your time and reimbursed for approved, study-related travel.

For info please contact:
Becky Nembhard, BS, CRC
Lead Clinical Research Coordinator
[email protected]
954-366-0277, ext 124

Infinity Clinical Research Working to Advance Progressive Treatments for Patients Through Clinical Trials

We have spaces open in this study. If you, or someone you know, would like more info please contact our trial coordinator:
Jorge Riveros
954-475-8171, x.120 or [email protected]

Do you have Mild Cognitive Impairment due to AD or mild AD dementia? If yes, and you are ages 60-85, you may be able to participate in a clinical study called ENVISION.

• Study treatment & health assessments provided at no cost
• You may be reimbursed for travel expenses
• You do not need to have health insurance to participate

Are you taking Gilenya or Tecfidera? Have you had a relapse in the last year? If YES we have a new research study for you.

The Artios Study: A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab study treatment effectiveness and participant-reported outcomes in people with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy. For ages 18-60.

For info, please call Michele at Infinity Clinical Research: 954-475-8171, x.134.